메뉴 건너뛰기




Volumn 13, Issue 1, 2006, Pages 21-25

Osteopenia in pediatric patients: When and how to intervene

Author keywords

Bisphosphonate; Bone density; Osteogenesis imperfecta; Osteopenia; Osteoporosis; Pamidronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; IBANDRONIC ACID; IBUPROFEN; OLPADRONIC ACID; PAMIDRONIC ACID; PARACETAMOL; ZOLEDRONIC ACID;

EID: 33646928327     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000198070.51574.da     Document Type: Review
Times cited : (2)

References (26)
  • 1
    • 3042858669 scopus 로고    scopus 로고
    • Bone health in children and adolescents: A symposium at the annual meeting of the Pediatric Academic Societies/Lawson Wilkins Pediatric Endocrine Society, May 2003
    • Gordon CM, Bachrach LK, Carpenter T, et al. Bone health in children and adolescents: a symposium at the annual meeting of the Pediatric Academic Societies/Lawson Wilkins Pediatric Endocrine Society, May 2003. Curr Probl Pediatr Adolesc Health Care 2004; 34:226-242. This is an excellent and comprehensive review of bone physiology, mechanisms of evaluating bone density, vitamin D supplementation in infants, and bisphosphonate therapy.
    • (2004) Curr Probl Pediatr Adolesc Health Care , vol.34 , pp. 226-242
    • Gordon, C.M.1    Bachrach, L.K.2    Carpenter, T.3
  • 2
    • 0032190352 scopus 로고    scopus 로고
    • Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
    • Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339:947-952.
    • (1998) N Engl J Med , vol.339 , pp. 947-952
    • Glorieux, F.H.1    Bishop, N.J.2    Plotkin, H.3
  • 3
    • 0034458026 scopus 로고    scopus 로고
    • Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age
    • Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85:1846-1850.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 1846-1850
    • Plotkin, H.1    Rauch, F.2    Bishop, N.J.3
  • 4
    • 0033679539 scopus 로고    scopus 로고
    • Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study
    • Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43:1960-1966.
    • (2000) Arthritis Rheum , vol.43 , pp. 1960-1966
    • Bianchi, M.L.1    Cimaz, R.2    Bardare, M.3
  • 5
    • 0036843182 scopus 로고    scopus 로고
    • Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial
    • Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141:644-651.
    • (2002) J Pediatr , vol.141 , pp. 644-651
    • Henderson, R.C.1    Lark, R.K.2    Kecskemethy, H.H.3
  • 6
    • 0036045172 scopus 로고    scopus 로고
    • Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome
    • Matarazzo P, Lala R, Masi G, et al. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15:929-937.
    • (2002) J Pediatr Endocrinol Metab , vol.15 , pp. 929-937
    • Matarazzo, P.1    Lala, R.2    Masi, G.3
  • 7
    • 0036250837 scopus 로고    scopus 로고
    • Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
    • Alstron E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86:356-364.
    • (2002) Arch Dis Child , vol.86 , pp. 356-364
    • Alstron, E.1    Soderhall, S.2
  • 8
    • 0036002592 scopus 로고    scopus 로고
    • Pamidronate treatment of osteogenesis imperfecta: Lack of correlation between clinical severity, age at onset of treatment, predicated collagen mutation and treatment response
    • Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicated collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15:163-174.
    • (2002) J Pediatr Endocrinol Metab , vol.15 , pp. 163-174
    • Zacharin, M.1    Bateman, J.2
  • 9
    • 0041304832 scopus 로고    scopus 로고
    • Bone mass, size, and density in children and adolescents with osteogenesis imperfecta; effect of intravenous pamidronate therapy
    • Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta; effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18:610-614.
    • (2003) J Bone Miner Res , vol.18 , pp. 610-614
    • Rauch, F.1    Plotkin, H.2    Zeitlin, L.3    Glorieux, F.H.4
  • 10
    • 0037736681 scopus 로고    scopus 로고
    • Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta
    • Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003; 111:e601-e603.
    • (2003) Pediatrics , vol.111
    • Montpetit, K.1    Plotkin, H.2    Rauch, F.3
  • 11
    • 0013409162 scopus 로고    scopus 로고
    • Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV
    • Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111:1030-1036.
    • (2003) Pediatrics , vol.111 , pp. 1030-1036
    • Zeitlin, L.1    Rauch, F.2    Plotkin, H.3    Glorieux, F.H.4
  • 12
    • 0036841117 scopus 로고    scopus 로고
    • The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta
    • Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110:1293-1299.
    • (2002) J Clin Invest , vol.110 , pp. 1293-1299
    • Rauch, F.1    Travers, R.2    Plotkin, H.3    Glorieux, F.H.4
  • 13
  • 14
    • 8444229279 scopus 로고    scopus 로고
    • Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta
    • DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35:1038-1045. This paper demonstrates that the treatment of patients with OI who are less than 3 years old may improve total body BMD and BMC and decrease fracture risk.
    • (2004) Bone , vol.35 , pp. 1038-1045
    • DiMeglio, L.A.1    Ford, L.2    McClintock, C.3    Peacock, M.4
  • 15
    • 23844448379 scopus 로고    scopus 로고
    • Bone densitometry in pediatric patients treated with pamidronate
    • Grissom L, Kecskemethy H, Bachrach S, et al. Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol 2005; 35:511-517. This paper describes patients with OI or cerebral palsy treated with pamidronate who had resulting increased lumbar-spine Z-scores on DEXA and a decreased fracture rate.
    • (2005) Pediatr Radiol , vol.35 , pp. 511-517
    • Grissom, L.1    Kecskemethy, H.2    Bachrach, S.3
  • 16
    • 2942726467 scopus 로고    scopus 로고
    • Strategic approaches to osteoporosis in transplantation
    • Mattano LA Jr. Strategic approaches to osteoporosis in transplantation. Pediatr Transplant 2004; 8 (Suppl. 5):51-55. This paper describes bone health in patients who have undergone stem cell transplantation.
    • (2004) Pediatr Transplant , vol.8 , Issue.5 SUPPL. , pp. 51-55
    • Mattano Jr., L.A.1
  • 17
    • 14644441700 scopus 로고    scopus 로고
    • Pamidronate treatment of pediatric fracture patients on chronic steroid therapy
    • Acott PD, Wong JA, Lang BA, Crocker JFS. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005; 20:368-373. This paper demonstrates the beneficial effects of pamidronate therapy on the bone density, fracture rate, and presence of bone pain in patients with the ongoing use of chronic steroids.
    • (2005) Pediatr Nephrol , vol.20 , pp. 368-373
    • Acott, P.D.1    Wong, J.A.2    Lang, B.A.3    Crocker, J.F.S.4
  • 18
    • 16644378418 scopus 로고    scopus 로고
    • Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate
    • Munns CFJ, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19:1779-1786. An observational study of 131 patients with OI taking pamidronate who either had a fracture or had an osteotomy performed. Patients taking pamidronate do not have delayed healing from fractures, but do have delayed healing after osteotomies.
    • (2004) J Bone Miner Res , vol.19 , pp. 1779-1786
    • Munns, C.F.J.1    Rauch, F.2    Zeitlin, L.3
  • 19
    • 1142310726 scopus 로고    scopus 로고
    • Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents
    • Robinson RF, Nahata MC, Hayes JR, et al. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 2004; 24:195-197. This study demonstrates that pre-treament with acetaminophen or ibuprofen decreases the acute-phase reaction that often occurs with the first dose of a bisphosphonate.
    • (2004) Pharmacotherapy , vol.24 , pp. 195-197
    • Robinson, R.F.1    Nahata, M.C.2    Hayes, J.R.3
  • 20
    • 0037287351 scopus 로고    scopus 로고
    • Zoledronic acid: A review of its use in the management of bone metastases and hypercalcemia of malignancy
    • Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcemia of malignancy. Drugs 2003; 63:417-437.
    • (2003) Drugs , vol.63 , pp. 417-437
    • Wellington, K.1    Goa, K.L.2
  • 21
    • 7444269603 scopus 로고    scopus 로고
    • Short-term safety assessment in the use of intravenous zoledronic acid in children
    • Hogler W, Yap F, Little D, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004; 145:701-704. This is a study of the safety and side-effect profile of an intravenous bisphosphonate more potent than pamidronate.
    • (2004) J Pediatr , vol.145 , pp. 701-704
    • Hogler, W.1    Yap, F.2    Little, D.3
  • 22
    • 8844282631 scopus 로고    scopus 로고
    • Bisphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases
    • Fernandes JL, Viana SL, Rocha AL, et al. Bisphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases. Skeletal Radiol 2004; 33:732-736. This paper shows the radiographic changes that occur with continuous bisphosphonate treatment.
    • (2004) Skeletal Radiol , vol.33 , pp. 732-736
    • Fernandes, J.L.1    Viana, S.L.2    Rocha, A.L.3
  • 23
    • 13644264359 scopus 로고    scopus 로고
    • A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta
    • DiMeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18:43-53. A short, small study comparing oral alendronate with intravenous bisphosphonate therapy in OI patients; oral therapy appears to be safe in this population, and may be equivalent in its effect on bone density and decreased fracture risk.
    • (2005) J Pediatr Endocrinol Metab , vol.18 , pp. 43-53
    • DiMeglio, L.A.1    Ford, L.2    McClintock, C.3    Peacock, M.4
  • 24
    • 17844388056 scopus 로고    scopus 로고
    • Oral bisphosphonates to treat disuse osteopenia in children with disabilities: A case series
    • Sholas MG, Tann B, Gaebler-Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. J Pediatr Orthop 2005; 25:326-331.
    • (2005) J Pediatr Orthop , vol.25 , pp. 326-331
    • Sholas, M.G.1    Tann, B.2    Gaebler-Spira, D.3
  • 25
    • 2342567864 scopus 로고    scopus 로고
    • Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomized placebo-controlled study
    • Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomized placebo-controlled study. Lancet 2004; 363:1427-1431. This study describes patients with OI who received olpadronate, an oral bisphosphonate, for 2 years and had a reduction in fracture risk as well as an increase in lumbar-spine DEXA Z-score.
    • (2004) Lancet , vol.363 , pp. 1427-1431
    • Sakkers, R.1    Kok, D.2    Engelbert, R.3
  • 26
    • 3242752905 scopus 로고    scopus 로고
    • Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy
    • Cundy T, Wheadon L, King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004; 19:703-711.
    • (2004) J Bone Miner Res , vol.19 , pp. 703-711
    • Cundy, T.1    Wheadon, L.2    King, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.